sunitinib ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 2544 557795-19-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sunitinib
  • sunitinib malate
  • sutent
  • SU-011248
  • SU-010398
  • PHA-290940AD
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
  • Molecular weight: 398.48
  • Formula: C22H27FN4O2
  • CLOGP: 3
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 77.23
  • ALOGS: -4.11
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
33 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.34 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 54.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 19, 2006 EMA Pfizer Limited
Jan. 26, 2006 FDA CPPI CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 1083.63 18.50 673 27922 95193 50481336
Palmar-plantar erythrodysaesthesia syndrome 764.71 18.50 321 28274 19777 50556752
Neoplasm progression 626.59 18.50 313 28282 28844 50547685
Death 482.60 18.50 742 27853 324637 50251892
Dysgeusia 402.73 18.50 259 28336 38657 50537872
Oral pain 387.66 18.50 216 28379 24817 50551712
Hypothyroidism 355.24 18.50 228 28367 33897 50542632
Yellow skin 352.64 18.50 101 28494 1928 50574601
Stomatitis 340.54 18.50 349 28246 100995 50475534
Diarrhoea 332.34 18.50 898 27697 587578 49988951
Thrombocytopenia 290.67 18.50 359 28236 127314 50449215
Drug ineffective 275.15 18.50 64 28531 819269 49757260
Hair colour changes 249.62 18.50 83 28512 2641 50573888
Decreased appetite 222.55 18.50 403 28192 200520 50376009
Hypertension 219.33 18.50 412 28183 210791 50365738
Platelet count decreased 217.51 18.50 276 28319 100450 50476079
Fatigue 184.59 18.50 837 27758 706764 49869765
Mucosal inflammation 137.73 18.50 140 28455 40002 50536527
Asthenia 129.59 18.50 435 28160 318607 50257922
Ageusia 116.98 18.50 76 28519 11507 50565022
Nausea 116.00 18.50 736 27859 704662 49871867
Vomiting 112.74 18.50 536 28059 460222 50116307
Dehydration 104.05 18.50 251 28344 152198 50424331
Blood pressure increased 101.57 18.50 229 28366 132903 50443626
Rheumatoid arthritis 100.75 18.50 3 28592 202547 50373982
Epistaxis 90.04 18.50 143 28452 63811 50512718
Oral discomfort 89.40 18.50 56 28539 7961 50568568
Dry skin 89.37 18.50 116 28479 43075 50533454
Dyspepsia 83.49 18.50 150 28445 73947 50502582
Drug hypersensitivity 82.92 18.50 20 28575 250990 50325539
Skin discolouration 80.64 18.50 96 28499 32661 50543868
Second primary malignancy 76.35 18.50 48 28547 6866 50569663
Arthropathy 69.94 18.50 5 28590 157901 50418628
Skin exfoliation 67.55 18.50 89 28506 33523 50543006
Blood thyroid stimulating hormone increased 64.04 18.50 41 28554 6051 50570478
Hyperkeratosis 63.36 18.50 38 28557 4997 50571532
Pleural effusion 63.04 18.50 141 28454 81313 50495216
Malignant neoplasm progression 59.67 18.50 124 28471 68000 50508529
Arthralgia 57.50 18.50 100 28495 438602 50137927
Tongue discomfort 55.19 18.50 25 28570 1843 50574686
Hypersensitivity 54.11 18.50 27 28568 215134 50361395
Ascites 52.96 18.50 82 28513 35779 50540750
Bone marrow failure 52.22 18.50 71 28524 27553 50548976
Sinusitis 51.76 18.50 16 28579 170542 50405987
Treatment failure 51.66 18.50 8 28587 137629 50438900
Joint swelling 47.83 18.50 41 28554 245245 50331284
Dry mouth 47.73 18.50 101 28494 56077 50520452
Osteonecrosis of jaw 47.50 18.50 74 28521 32452 50544077
Renal cell carcinoma 45.77 18.50 26 28569 3091 50573438
Flatulence 41.60 18.50 66 28529 29392 50547137
Blister 41.37 18.50 124 28471 85294 50491235
Jaundice 41.23 18.50 62 28533 26367 50550162
Swelling 41.11 18.50 32 28563 200840 50375689
Therapeutic product effect incomplete 40.21 18.50 3 28592 91512 50485017
Pancreatic neuroendocrine tumour 39.77 18.50 12 28583 276 50576253
White blood cell count decreased 39.33 18.50 150 28445 116572 50459957
Metastases to liver 38.49 18.50 52 28543 20052 50556477
Urticaria 37.80 18.50 13 28582 129548 50446981
Gingival pain 36.62 18.50 29 28566 5977 50570552
Pancytopenia 36.08 18.50 117 28478 83913 50492616
Face oedema 35.46 18.50 47 28548 17792 50558737
Nephritic syndrome 35.14 18.50 10 28585 186 50576343
Discomfort 35.03 18.50 9 28586 108371 50468158
Metastatic renal cell carcinoma 34.86 18.50 14 28581 766 50575763
Condition aggravated 34.23 18.50 73 28522 296985 50279544
Plantar erythema 33.87 18.50 10 28585 213 50576316
Tumour haemorrhage 33.40 18.50 16 28579 1339 50575190
Thyroid disorder 32.59 18.50 38 28557 12639 50563890
Eyelid oedema 32.41 18.50 33 28562 9433 50567096
Neutropenia 32.27 18.50 167 28428 147798 50428731
Off label use 31.82 18.50 149 28446 474277 50102252
Renal cancer metastatic 31.59 18.50 10 28585 271 50576258
Musculoskeletal stiffness 30.97 18.50 17 28578 128464 50448065
Gingival bleeding 30.81 18.50 35 28560 11318 50565211
Blood lactate dehydrogenase increased 30.67 18.50 46 28549 19516 50557013
Asthma 29.68 18.50 7 28588 89330 50487199
Disseminated intravascular coagulation 29.33 18.50 42 28553 17093 50559436
Neoplasm malignant 29.26 18.50 50 28545 23665 50552864
Gastrointestinal stromal tumour 29.22 18.50 13 28582 918 50575611
Infection 28.98 18.50 33 28562 172921 50403608
Soft tissue sarcoma 28.70 18.50 7 28588 69 50576460
Generalised oedema 28.57 18.50 37 28558 13694 50562835
Chromaturia 28.33 18.50 38 28557 14552 50561977
Psoriasis 28.32 18.50 3 28592 68997 50507532
Hypogeusia 27.08 18.50 13 28582 1093 50575436
Eating disorder 26.71 18.50 38 28557 15371 50561158
Taste disorder 26.66 18.50 28 28567 8296 50568233
Skin toxicity 26.26 18.50 20 28575 3893 50572636
Pain 26.11 18.50 206 28389 578697 49997832
Proteinuria 25.98 18.50 39 28556 16558 50559971
General physical health deterioration 25.22 18.50 152 28443 142282 50434247
Mobility decreased 25.15 18.50 7 28588 79941 50496588
Nephrotic syndrome 24.81 18.50 21 28574 4749 50571780
Weight decreased 24.59 18.50 211 28384 221034 50355495
Pericarditis 24.55 18.50 7 28588 78682 50497847
Drug interaction 23.86 18.50 48 28547 199573 50376956
Anaemia 23.62 18.50 232 28363 252224 50324305
Thyroiditis 23.57 18.50 14 28581 1808 50574721
Hyperaesthesia 23.56 18.50 26 28569 8147 50568382
Bronchitis 23.38 18.50 15 28580 104144 50472385
Oral mucosal blistering 22.63 18.50 20 28575 4792 50571737
Fall 22.52 18.50 105 28490 334827 50241702
Periorbital oedema 21.93 18.50 20 28575 4992 50571537
Pneumonia 21.86 18.50 125 28470 378276 50198253
Eyelash discolouration 21.32 18.50 5 28590 41 50576488
Chest discomfort 21.30 18.50 13 28582 92709 50483820
Glossitis 21.04 18.50 15 28580 2640 50573889
Pain in extremity 20.51 18.50 240 28355 272625 50303904
Metastases to lung 20.33 18.50 28 28567 10992 50565537
Thyroid function test abnormal 20.12 18.50 16 28579 3316 50573213
Injection site pain 19.90 18.50 20 28575 111004 50465525
Metastases to central nervous system 19.82 18.50 28 28567 11254 50565275
Drug intolerance 19.70 18.50 61 28534 219043 50357486
Feeding disorder 19.63 18.50 27 28568 10586 50565943
Hepatic infection bacterial 19.44 18.50 3 28592 0 50576529
Suicide attempt 19.41 18.50 3 28592 51729 50524800
Dyspnoea 19.40 18.50 207 28388 547401 50029128
Hypertensive crisis 19.30 18.50 30 28565 13124 50563405
Tongue blistering 19.06 18.50 11 28584 1347 50575182
Petechiae 19.01 18.50 29 28566 12483 50564046
Nasopharyngitis 18.58 18.50 52 28543 192875 50383654
Anxiety 18.53 18.50 46 28549 177560 50398969

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 2194.70 14.87 1429 43769 80487 29448842
Neoplasm progression 1252.29 14.87 597 44601 18015 29511314
Palmar-plantar erythrodysaesthesia syndrome 1209.91 14.87 543 44655 14216 29515113
Death 733.61 14.87 1607 43591 340477 29188852
Dysgeusia 689.31 14.87 430 44768 22244 29507085
Yellow skin 451.34 14.87 152 45046 1766 29527563
Diarrhoea 450.31 14.87 1315 43883 331383 29197946
Stomatitis 435.45 14.87 398 44800 36715 29492614
Osteonecrosis of jaw 403.03 14.87 273 44925 16237 29513092
Oral pain 378.12 14.87 213 44985 9094 29520235
Fatigue 366.22 14.87 1186 44012 315635 29213694
Hair colour changes 345.11 14.87 119 45079 1492 29527837
Hypothyroidism 338.98 14.87 242 44956 15664 29513665
Hypertension 311.00 14.87 602 44596 116012 29413317
Decreased appetite 304.16 14.87 679 44519 144663 29384666
Ageusia 282.71 14.87 174 45024 8764 29520565
Glossodynia 258.00 14.87 117 45081 3126 29526203
Drug ineffective 221.36 14.87 142 45056 363028 29166301
Dyspepsia 156.56 14.87 211 44987 29914 29499415
Dry skin 155.65 14.87 185 45013 23122 29506207
Platelet count decreased 154.98 14.87 429 44769 104243 29425086
Mucosal inflammation 148.75 14.87 211 44987 31384 29497945
Asthenia 146.33 14.87 683 44515 214567 29314762
Nausea 134.08 14.87 826 44372 288429 29240900
Blood pressure increased 133.30 14.87 326 44872 73477 29455852
Thrombocytopenia 121.09 14.87 466 44732 134357 29394972
Completed suicide 119.96 14.87 4 45194 90242 29439087
Drug interaction 118.71 14.87 78 45120 197307 29332022
Off label use 116.59 14.87 175 45023 300625 29228704
Blister 113.56 14.87 146 45052 19760 29509569
Second primary malignancy 98.84 14.87 82 45116 6623 29522706
Drug abuse 98.16 14.87 6 45192 79877 29449452
Blood thyroid stimulating hormone increased 97.01 14.87 60 45138 3045 29526284
Skin exfoliation 90.39 14.87 140 45058 22505 29506824
Skin discolouration 89.43 14.87 114 45084 15295 29514034
Renal cell carcinoma 83.25 14.87 64 45134 4632 29524697
Febrile neutropenia 81.11 14.87 35 45163 112205 29417124
Oral discomfort 79.26 14.87 48 45150 2345 29526984
Epistaxis 76.44 14.87 212 44986 51492 29477837
Renal cancer metastatic 71.76 14.87 27 45171 441 29528888
Pleural effusion 68.09 14.87 253 44945 71655 29457674
Hyperkeratosis 67.89 14.87 49 45149 3220 29526109
Exposed bone in jaw 65.76 14.87 36 45162 1450 29527879
Neoplasm malignant 65.26 14.87 103 45095 16822 29512507
Overdose 64.15 14.87 21 45177 79798 29449531
Vomiting 63.75 14.87 547 44651 211713 29317616
Gingival pain 59.57 14.87 38 45160 2036 29527293
Acute kidney injury 57.04 14.87 211 44987 265056 29264273
Cardiopulmonary failure 55.94 14.87 46 45152 3668 29525661
Hypotension 55.08 14.87 136 45062 194218 29335111
Malignant neoplasm progression 54.86 14.87 241 44957 73618 29455711
Fall 53.37 14.87 120 45078 177058 29352271
Dry mouth 52.45 14.87 108 45090 21676 29507653
Gastrointestinal stromal tumour 52.28 14.87 25 45173 755 29528574
Dehydration 51.12 14.87 325 44873 114423 29414906
Tongue discomfort 49.23 14.87 21 45177 482 29528847
Metastatic renal cell carcinoma 47.67 14.87 32 45166 1870 29527459
Intentional overdose 46.99 14.87 3 45195 38525 29490804
Pneumonia 45.97 14.87 294 44904 319878 29209451
Aortic dissection 45.59 14.87 34 45164 2350 29526979
Thyroid function test abnormal 43.71 14.87 21 45177 641 29528688
Hypogeusia 43.41 14.87 23 45175 867 29528462
Bone marrow failure 41.98 14.87 114 45084 27335 29501994
Oral mucosal blistering 41.83 14.87 28 45170 1629 29527700
Tongue blistering 41.53 14.87 15 45183 217 29529112
Suicidal ideation 41.47 14.87 3 45195 34713 29494616
Oxygen saturation decreased 41.43 14.87 9 45189 44928 29484401
Proteinuria 41.20 14.87 81 45117 15723 29513606
Weight decreased 41.14 14.87 381 44817 150524 29378805
Tachycardia 40.29 14.87 31 45167 72379 29456950
Aggression 39.91 14.87 4 45194 35537 29493792
Atrial fibrillation 39.27 14.87 63 45135 105583 29423746
Pain in extremity 38.69 14.87 295 44903 110138 29419191
Drug hypersensitivity 38.42 14.87 29 45169 68377 29460952
Abdominal discomfort 38.39 14.87 160 45038 47743 29481586
Skin fissures 38.21 14.87 38 45160 3881 29525448
Therapeutic product effect incomplete 38.05 14.87 7 45191 39298 29490031
Urticaria 37.96 14.87 18 45180 54642 29474687
Wrong technique in product usage process 36.73 14.87 3 45195 31425 29497904
Metastases to liver 36.18 14.87 65 45133 11791 29517538
COVID-19 35.77 14.87 6 45192 36008 29493321
Taste disorder 35.36 14.87 40 45158 4736 29524593
Plasma cell myeloma 35.10 14.87 7 45191 37108 29492221
Asthma 35.07 14.87 5 45193 33844 29495485
Impaired healing 34.75 14.87 69 45129 13489 29515840
Intentional product use issue 34.45 14.87 11 45187 42487 29486842
White blood cell count decreased 33.98 14.87 231 44967 83131 29446198
Anal abscess 33.91 14.87 41 45157 5210 29524119
Rhabdomyolysis 33.86 14.87 26 45172 60782 29468547
Anxiety 33.55 14.87 49 45149 85316 29444013
Thyroid disorder 33.44 14.87 30 45168 2692 29526637
Suicide attempt 33.18 14.87 6 45192 34104 29495225
Psoriasis 32.84 14.87 5 45193 32222 29497107
Ascites 32.28 14.87 126 45072 36493 29492836
Myxoedema 32.20 14.87 7 45191 10 29529319
Metastases to lung 31.94 14.87 49 45149 7806 29521523
Drug reaction with eosinophilia and systemic symptoms 31.83 14.87 3 45195 27989 29501340
Agitation 31.12 14.87 20 45178 51284 29478045
Product dose omission issue 30.87 14.87 63 45135 96320 29433009
Inappropriate schedule of product administration 30.33 14.87 15 45183 44457 29484872
Periorbital oedema 30.23 14.87 31 45167 3284 29526045
Hospitalisation 29.19 14.87 17 45181 45971 29483358
Hyperaesthesia 29.05 14.87 31 45167 3438 29525891
Coronary artery disease 28.52 14.87 16 45182 44174 29485155
Condition aggravated 28.41 14.87 121 45077 146174 29383155
Blood creatinine increased 27.94 14.87 224 44974 84878 29444451
Nephrotic syndrome 27.90 14.87 41 45157 6287 29523042
Cardio-respiratory arrest 27.71 14.87 22 45176 50579 29478750
Disseminated intravascular coagulation 27.61 14.87 80 45118 19900 29509429
Flatulence 27.52 14.87 74 45124 17635 29511694
Hyperhidrosis 27.42 14.87 35 45163 64505 29464824
Cardiac arrest 27.36 14.87 56 45142 85535 29443794
Skin disorder 27.26 14.87 57 45141 11561 29517768
Gastrointestinal toxicity 27.20 14.87 24 45174 2107 29527222
Tremor 27.18 14.87 44 45154 73494 29455835
Pain in jaw 27.18 14.87 57 45141 11584 29517745
Acute respiratory failure 27.12 14.87 4 45194 26398 29502931
Mouth ulceration 26.90 14.87 53 45145 10302 29519027
Glossitis 26.84 14.87 18 45180 1050 29528279
Abdominal pain 26.61 14.87 320 44878 135037 29394292
Gastrooesophageal reflux disease 25.85 14.87 106 45092 31390 29497939
Tumour compression 25.73 14.87 9 45189 118 29529211
Constipation 25.17 14.87 276 44922 113884 29415445
Jaundice 25.16 14.87 100 45098 29196 29500133
Jaw fistula 24.84 14.87 7 45191 42 29529287
Anaemia 24.80 14.87 438 44760 200513 29328816
Intentional product misuse 24.70 14.87 11 45187 34650 29494679
Tumour rupture 24.53 14.87 10 45188 204 29529125
Delirium 24.39 14.87 15 45183 39382 29489947
Pancreatic neuroendocrine tumour metastatic 24.30 14.87 8 45190 86 29529243
Hypoxia 24.23 14.87 22 45176 47357 29481972
General physical health deterioration 23.75 14.87 251 44947 102606 29426723
Tumour necrosis 23.51 14.87 17 45181 1120 29528209
Wheezing 22.99 14.87 11 45187 33229 29496100
Hypertensive crisis 22.64 14.87 42 45156 7806 29521523
Metastases to bone 22.57 14.87 48 45150 9850 29519479
Hypersensitivity 22.15 14.87 29 45169 52874 29476455
Treatment noncompliance 22.03 14.87 5 45193 24222 29505107
Adverse drug reaction 21.75 14.87 5 45193 24015 29505314
Sinusitis 21.37 14.87 13 45185 34337 29494992
Anaphylactic reaction 20.86 14.87 8 45190 27565 29501764
Septic shock 20.79 14.87 40 45158 62520 29466809
Performance status decreased 20.72 14.87 27 45171 3700 29525629
Injection site pain 20.58 14.87 12 45186 32434 29496895
Osteonecrosis 20.51 14.87 56 45142 13463 29515866
Gingival bleeding 20.48 14.87 36 45162 6417 29522912
Skin toxicity 20.47 14.87 27 45171 3744 29525585
Tumour haemorrhage 20.45 14.87 22 45176 2463 29526866
Treatment failure 20.30 14.87 16 45182 36923 29492406
Medication error 20.06 14.87 4 45194 21207 29508122
Haemoptysis 19.92 14.87 96 45102 30454 29498875
Chronic obstructive pulmonary disease 19.79 14.87 20 45178 40935 29488394
Malaise 19.71 14.87 348 44850 159254 29370075
Unresponsive to stimuli 19.50 14.87 7 45191 25119 29504210
Dental fistula 19.33 14.87 7 45191 102 29529227
Face oedema 19.13 14.87 46 45152 10237 29519092
Drug level increased 18.94 14.87 3 45195 18784 29510545
Anal ulcer 18.76 14.87 12 45186 646 29528683
Respiratory arrest 18.72 14.87 8 45190 25825 29503504
Pulmonary hypertension 18.70 14.87 3 45195 18605 29510724
Depression 18.70 14.87 67 45131 85080 29444249
Dyskinesia 18.52 14.87 4 45194 20057 29509272
Bradycardia 18.47 14.87 46 45152 65583 29463746
Musculoskeletal stiffness 18.44 14.87 18 45180 37440 29491889
Ejection fraction decreased 18.37 14.87 60 45138 15918 29513411
Cholecystitis 18.04 14.87 42 45156 9155 29520174
Metastases to central nervous system 17.92 14.87 36 45162 7095 29522234
Bronchitis 17.82 14.87 18 45180 36850 29492479
Blood lactate dehydrogenase increased 17.66 14.87 67 45131 19142 29510187
Skin ulcer 17.56 14.87 66 45132 18774 29510555
Upper respiratory tract infection 17.51 14.87 10 45188 27339 29501990
Dysarthria 17.48 14.87 13 45185 30898 29498431
Restlessness 17.47 14.87 6 45192 22139 29507190
Gingivitis 17.43 14.87 22 45176 2920 29526409
Therapeutic response decreased 17.36 14.87 8 45190 24703 29504626
Lacrimation increased 17.26 14.87 35 45163 6945 29522384
Hallucination 17.23 14.87 26 45172 44686 29484643
Agranulocytosis 16.96 14.87 5 45193 20335 29508994
Gingival swelling 16.95 14.87 14 45184 1123 29528206
Staphylococcal infection 16.92 14.87 12 45186 29228 29500101
Stress 16.65 14.87 6 45192 21484 29507845
Angular cheilitis 16.48 14.87 7 45191 159 29529170
Scrotal inflammation 16.46 14.87 3 45195 0 29529329
Appetite disorder 16.45 14.87 18 45180 2054 29527275
Eating disorder 16.35 14.87 35 45163 7212 29522117
Anorectal discomfort 16.34 14.87 16 45182 1603 29527726
Pericardial effusion 16.33 14.87 70 45128 21138 29508191
Cancer pain 16.27 14.87 19 45179 2328 29527001
Neoplasm of thymus 15.73 14.87 4 45194 15 29529314
Skin lesion 15.63 14.87 63 45135 18509 29510820
Myelodysplastic syndrome 15.53 14.87 4 45194 17790 29511539
Periodontal disease 15.24 14.87 11 45187 723 29528606
Hypervolaemia 15.21 14.87 4 45194 17541 29511788
Seizure 15.15 14.87 82 45116 93041 29436288
Unevaluable event 15.09 14.87 14 45184 29837 29499492
Soft tissue sarcoma 15.09 14.87 5 45193 55 29529274
Product quality issue 15.02 14.87 3 45195 15892 29513437
Incorrect dose administered 14.94 14.87 17 45181 32967 29496362

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 2474.59 15.05 1607 62012 140073 64295040
Palmar-plantar erythrodysaesthesia syndrome 1746.97 15.05 753 62866 28066 64407047
Neoplasm progression 1651.49 15.05 806 62813 40158 64394955
Dysgeusia 1012.88 15.05 611 63008 46436 64388677
Death 779.25 15.05 1562 62057 481143 63953970
Diarrhoea 757.01 15.05 1969 61650 720735 63714378
Oral pain 683.22 15.05 392 63227 27101 64408012
Yellow skin 664.75 15.05 206 63413 2893 64432220
Stomatitis 660.94 15.05 669 62950 108936 64326177
Hypothyroidism 604.90 15.05 418 63201 40039 64395074
Decreased appetite 557.24 15.05 995 62624 280294 64154819
Hair colour changes 528.21 15.05 181 63438 3546 64431567
Fatigue 519.72 15.05 1765 61854 746965 63688148
Hypertension 441.65 15.05 860 62759 258401 64176712
Ageusia 425.55 15.05 227 63392 13586 64421527
Drug ineffective 400.97 15.05 165 63454 840082 63595031
Platelet count decreased 368.87 15.05 622 62997 167089 64268024
Osteonecrosis of jaw 327.52 15.05 289 63330 39536 64395577
Thrombocytopenia 321.16 15.05 692 62927 223109 64212004
Asthenia 299.42 15.05 1014 62605 427030 64008083
Dry skin 259.30 15.05 285 63334 50876 64384237
Mucosal inflammation 254.11 15.05 311 63308 62273 64372840
Dyspepsia 220.59 15.05 330 63289 79982 64355131
Completed suicide 197.77 15.05 5 63614 224409 64210704
Blood pressure increased 185.51 15.05 477 63142 172075 64263038
Nausea 182.50 15.05 1360 62259 784440 63650673
Second primary malignancy 162.33 15.05 118 63501 12219 64422894
Skin exfoliation 153.67 15.05 205 63414 44680 64390433
Epistaxis 149.16 15.05 311 63308 97820 64337293
Rheumatoid arthritis 147.28 15.05 3 63616 164291 64270822
Drug hypersensitivity 141.16 15.05 31 63588 237784 64197329
Skin discolouration 139.49 15.05 173 63446 35082 64400031
Pleural effusion 139.18 15.05 353 63266 126206 64308907
Oral discomfort 135.35 15.05 91 63528 8315 64426798
Blood thyroid stimulating hormone increased 133.26 15.05 87 63532 7567 64427546
Vomiting 124.68 15.05 949 62670 550168 63884945
Hyperkeratosis 123.86 15.05 79 63540 6602 64428511
Dehydration 116.91 15.05 473 63146 216290 64218823
Drug interaction 116.91 15.05 111 63508 361972 64073141
Drug abuse 106.21 15.05 6 63613 132368 64302745
Dry mouth 105.56 15.05 203 63416 60215 64374898
Blister 104.14 15.05 240 63379 80727 64354386
Overdose 102.71 15.05 17 63602 159549 64275564
Off label use 102.29 15.05 304 63315 632502 63802611
Bone marrow failure 101.38 15.05 175 63444 47777 64387336
Malignant neoplasm progression 97.31 15.05 288 63331 112583 64322530
Glossodynia 93.58 15.05 201 63418 64495 64370618
Gingival pain 93.21 15.05 65 63554 6302 64428811
Tongue discomfort 92.57 15.05 44 63575 2055 64433058
Weight decreased 89.60 15.05 534 63085 285205 64149908
Hypersensitivity 89.28 15.05 41 63578 196411 64238702
Hypogeusia 80.14 15.05 36 63583 1475 64433638
Ascites 79.95 15.05 184 63435 61817 64373296
Renal cell carcinoma 79.43 15.05 58 63561 6046 64429067
White blood cell count decreased 78.42 15.05 336 63283 157501 64277612
Sinusitis 77.06 15.05 24 63595 145904 64289209
Taste disorder 76.59 15.05 68 63551 9365 64425748
Arthropathy 75.41 15.05 14 63605 120953 64314160
Urticaria 72.98 15.05 27 63592 147290 64287823
Intentional overdose 72.38 15.05 4 63615 89940 64345173
Therapeutic product effect incomplete 68.91 15.05 10 63609 103472 64331641
Flatulence 67.46 15.05 124 63495 35542 64399571
Disseminated intravascular coagulation 66.99 15.05 117 63502 32231 64402882
Aortic dissection 66.94 15.05 42 63577 3410 64431703
Fall 65.93 15.05 202 63417 416624 64018489
Renal cancer metastatic 65.81 15.05 25 63594 664 64434449
Treatment failure 63.88 15.05 18 63601 116798 64318315
Proteinuria 63.66 15.05 105 63514 27618 64407495
Condition aggravated 62.13 15.05 176 63443 372250 64062863
Intentional product use issue 61.71 15.05 10 63609 95354 64339759
Febrile neutropenia 61.09 15.05 57 63562 187600 64247513
Arthralgia 60.64 15.05 228 63391 442032 63993081
Gastrointestinal stromal tumour 60.46 15.05 29 63590 1382 64433731
Metastases to liver 59.51 15.05 94 63525 23847 64411266
Anaemia 58.78 15.05 601 63018 378079 64057034
Joint swelling 58.47 15.05 76 63543 215306 64219807
Oral mucosal blistering 57.59 15.05 45 63574 5192 64429921
Asthma 57.29 15.05 12 63607 95213 64339900
General physical health deterioration 55.25 15.05 368 63251 204057 64231056
Jaundice 52.93 15.05 135 63484 48377 64386736
Thyroid disorder 52.16 15.05 61 63558 11631 64423482
Wrong technique in product usage process 51.93 15.05 3 63616 64971 64370142
Hypotension 51.16 15.05 198 63421 380776 64054337
Musculoskeletal stiffness 51.04 15.05 29 63590 123177 64311936
Oxygen saturation decreased 50.83 15.05 21 63598 107155 64327958
Thyroid function test abnormal 50.79 15.05 33 63586 2846 64432267
Psoriasis 49.96 15.05 6 63613 71697 64363416
Tumour haemorrhage 49.59 15.05 35 63584 3458 64431655
Tachycardia 48.01 15.05 46 63573 149533 64285580
Tongue blistering 47.72 15.05 24 63595 1269 64433844
Hyperaesthesia 47.62 15.05 54 63565 9960 64425153
Anal abscess 47.27 15.05 47 63572 7461 64427652
Suicide attempt 46.95 15.05 7 63612 71000 64364113
Acute kidney injury 46.94 15.05 256 63363 448984 63986129
Wheezing 46.76 15.05 11 63608 80568 64354545
Nephrotic syndrome 46.20 15.05 52 63567 9515 64425598
Pneumonia 45.17 15.05 345 63274 559231 63875882
Periorbital oedema 44.09 15.05 45 63574 7369 64427744
Pain in extremity 43.21 15.05 473 63146 302612 64132501
Eating disorder 43.18 15.05 67 63552 16738 64418375
Suicidal ideation 42.99 15.05 7 63612 66535 64368578
Glossitis 42.58 15.05 31 63588 3216 64431897
Osteoarthritis 42.44 15.05 6 63613 63330 64371783
Gingival bleeding 42.11 15.05 62 63557 14792 64420321
Eyelid oedema 41.87 15.05 56 63563 12223 64422890
Drug reaction with eosinophilia and systemic symptoms 41.86 15.05 3 63616 54214 64380899
Hypertensive crisis 41.74 15.05 69 63550 18179 64416934
Bronchitis 41.70 15.05 28 63591 108715 64326398
Blood lactate dehydrogenase increased 41.35 15.05 97 63522 32981 64402132
Injection site pain 40.99 15.05 30 63589 111378 64323735
Skin toxicity 40.96 15.05 41 63578 6561 64428552
Chromaturia 40.74 15.05 77 63542 22534 64412579
Anxiety 40.62 15.05 87 63532 202562 64232551
Exposed bone in jaw 40.60 15.05 31 63588 3456 64431657
Constipation 40.43 15.05 374 63245 228963 64206150
Mobility decreased 38.83 15.05 18 63601 85822 64349291
Tumour necrosis 38.80 15.05 23 63596 1686 64433427
Anaphylactic reaction 38.63 15.05 10 63609 68654 64366459
Gastrooesophageal reflux disease 38.21 15.05 173 63446 82970 64352143
COVID-19 37.59 15.05 9 63610 65131 64369982
Face oedema 35.86 15.05 77 63542 24684 64410429
Chest discomfort 35.77 15.05 37 63582 116069 64319044
Skin disorder 35.51 15.05 82 63537 27598 64407515
Atrial fibrillation 35.50 15.05 72 63547 171017 64264096
Cardiac arrest 35.35 15.05 61 63558 154003 64281110
Medication error 35.26 15.05 4 63615 49962 64385151
Soft tissue sarcoma 35.08 15.05 10 63609 103 64435010
Performance status decreased 34.55 15.05 34 63585 5330 64429783
Skin fissures 33.62 15.05 46 63573 10260 64424853
Metastatic renal cell carcinoma 33.51 15.05 23 63596 2173 64432940
Blood creatinine increased 33.43 15.05 239 63380 135543 64299570
Nasopharyngitis 33.13 15.05 92 63527 195981 64239132
Intentional product misuse 32.95 15.05 15 63604 72280 64362833
Hyperhidrosis 32.94 15.05 45 63574 124875 64310238
Plantar erythema 32.93 15.05 12 63607 283 64434830
Ill-defined disorder 32.45 15.05 3 63616 44049 64391064
Agitation 32.24 15.05 24 63595 88343 64346770
Drug intolerance 31.91 15.05 88 63531 187904 64247209
Aggression 31.88 15.05 4 63615 46228 64388885
Cardio-respiratory arrest 31.87 15.05 30 63589 98363 64336750
Metastases to lung 31.33 15.05 55 63564 15209 64419904
Metastases to central nervous system 31.01 15.05 52 63567 13860 64421253
Eyelash discolouration 30.80 15.05 8 63611 56 64435057
Osteoporosis 30.64 15.05 3 63616 42077 64393036
Dyspnoea 30.60 15.05 512 63107 718162 63716951
Tumour rupture 30.57 15.05 12 63607 349 64434764
Feeding disorder 29.67 15.05 49 63570 12900 64422213
Plasma cell myeloma 29.42 15.05 5 63614 46070 64389043
Myxoedema 29.39 15.05 9 63610 121 64434992
Cancer pain 29.33 15.05 28 63591 4229 64430884
Psoriatic arthropathy 29.23 15.05 4 63615 43277 64391836
Generalised oedema 29.23 15.05 64 63555 20789 64414324
Unresponsive to stimuli 29.00 15.05 7 63612 50386 64384727
Swelling 28.71 15.05 73 63546 160145 64274968
Heart rate increased 28.67 15.05 33 63586 98642 64336471
Injury 28.16 15.05 10 63609 55982 64379131
Mouth ulceration 28.13 15.05 83 63536 32361 64402752
Gingival discomfort 27.71 15.05 10 63609 229 64434884
Upper respiratory tract infection 27.56 15.05 19 63600 72766 64362347
Injection site swelling 27.51 15.05 4 63615 41349 64393764
Malaise 27.23 15.05 545 63074 395702 64039411
Thyroiditis 27.20 15.05 25 63594 3599 64431514
Electrocardiogram QT prolonged 27.19 15.05 23 63596 79425 64355688
Hiccups 26.74 15.05 37 63582 8339 64426774
Pancreatic neuroendocrine tumour metastatic 26.73 15.05 8 63611 99 64435014
Inappropriate schedule of product administration 25.60 15.05 32 63587 92254 64342859
Migraine 25.60 15.05 15 63604 62662 64372451
Pericarditis 25.48 15.05 15 63604 62501 64372612
Therapy non-responder 25.22 15.05 17 63602 65882 64369231
Chronic obstructive pulmonary disease 25.02 15.05 20 63599 71028 64364085
Lower respiratory tract infection 25.02 15.05 34 63585 94580 64340533
Acute respiratory failure 24.97 15.05 9 63610 49925 64385188
Hypervolaemia 24.79 15.05 4 63615 38281 64396832
Tremor 24.70 15.05 70 63549 148160 64286953
Pneumatosis intestinalis 24.53 15.05 28 63591 5201 64429912
Incorrect dose administered 24.17 15.05 15 63604 60750 64374363
Gastrointestinal toxicity 24.13 15.05 28 63591 5294 64429819
Pruritus 24.02 15.05 195 63424 312205 64122908
Pancreatic neuroendocrine tumour 23.90 15.05 11 63608 477 64434636
Gingival swelling 23.69 15.05 24 63595 3896 64431217
Mouth haemorrhage 23.64 15.05 38 63581 9781 64425332
Tumour compression 23.61 15.05 8 63611 151 64434962
Dyskinesia 23.61 15.05 5 63614 39383 64395730
Hyperthyroidism 23.47 15.05 54 63565 18125 64416988
Hyperchlorhydria 23.19 15.05 17 63602 1782 64433331
Nephritic syndrome 23.08 15.05 9 63610 257 64434856
Accidental overdose 22.90 15.05 3 63616 33554 64401559
Renal cancer 22.90 15.05 31 63588 6844 64428269
Blood glucose decreased 22.82 15.05 62 63557 23061 64412052
Emotional distress 22.82 15.05 4 63615 36034 64399079
Haemoptysis 22.48 15.05 102 63517 48946 64386167
Skin lesion 22.37 15.05 83 63536 36399 64398714
Neoplasm malignant 22.21 15.05 64 63555 24624 64410489
Jaw fistula 22.15 15.05 7 63612 105 64435008
Anorectal discomfort 21.85 15.05 20 63599 2865 64432248
Abdominal pain 21.56 15.05 430 63189 311945 64123168
Treatment noncompliance 21.47 15.05 8 63611 43474 64391639
Product dose omission issue 21.38 15.05 109 63510 194638 64240475
Stress 21.37 15.05 17 63602 60517 64374596
Coronary artery disease 21.30 15.05 17 63602 60416 64374697
Drug level increased 21.21 15.05 4 63615 34192 64400921
Therapeutic response decreased 20.60 15.05 13 63606 52175 64382938
Discomfort 20.45 15.05 30 63589 80848 64354265
Rhabdomyolysis 20.41 15.05 37 63582 91689 64343424
Metastases to bone 20.38 15.05 55 63564 20380 64414733
Delirium 20.25 15.05 23 63596 69171 64365942
Palpitations 19.98 15.05 46 63573 104442 64330671
Respiratory arrest 19.83 15.05 14 63605 52971 64382142
Pericardial effusion 19.79 15.05 84 63535 39170 64395943
Hypoalbuminaemia 19.08 15.05 49 63570 17625 64417488
Agranulocytosis 18.93 15.05 7 63612 38222 64396891
Hospitalisation 18.92 15.05 28 63591 75179 64359934
Depression 18.78 15.05 105 63514 183186 64251927
Cholecystitis 18.73 15.05 52 63567 19584 64415529
Clear cell sarcoma of soft tissue 18.69 15.05 4 63615 10 64435103
Drug-induced liver injury 18.62 15.05 12 63607 47631 64387482
Hypokalaemia 18.56 15.05 60 63559 121843 64313270
Arthritis 18.48 15.05 34 63585 83780 64351333
Drug dependence 18.45 15.05 5 63614 33307 64401806
Nasal congestion 18.38 15.05 19 63600 59639 64375474
Appetite disorder 18.36 15.05 27 63592 6434 64428679
Hypoxia 18.35 15.05 37 63582 88112 64347001
Product prescribing error 18.25 15.05 6 63613 35263 64399850
Leukopenia 17.75 15.05 165 63454 101077 64334036
International normalised ratio increased 17.56 15.05 32 63587 79135 64355978
Pulmonary fibrosis 17.49 15.05 4 63615 29874 64405239
Hallucination 17.45 15.05 28 63591 72760 64362353
Oesophagitis ulcerative 17.44 15.05 11 63608 901 64434212
Haematemesis 17.43 15.05 92 63527 46907 64388206
Product quality issue 17.42 15.05 4 63615 29795 64405318
Influenza 17.23 15.05 51 63568 106480 64328633
Coma 17.22 15.05 38 63581 87577 64347536
Dysarthria 17.11 15.05 20 63599 59386 64375727
Hepatic enzyme increased 17.10 15.05 68 63551 129875 64305238
Rash maculo-papular 16.86 15.05 13 63606 47013 64388100
Oral disorder 16.84 15.05 31 63588 8890 64426223
Infection 16.80 15.05 110 63509 184770 64250343
Drug withdrawal syndrome 16.77 15.05 5 63614 31286 64403827
Red blood cell sedimentation rate increased 16.72 15.05 5 63614 31230 64403883
Angioedema 16.56 15.05 22 63597 61799 64373314
Flushing 16.38 15.05 33 63586 78615 64356498
Haematuria 16.38 15.05 109 63510 60362 64374751
Lactic acidosis 16.30 15.05 22 63597 61388 64373725
Neoplasm of thymus 16.23 15.05 4 63615 22 64435091
Tumour pain 15.82 15.05 14 63605 1919 64433194
Blastic plasmacytoid dendritic cell neoplasia 15.70 15.05 5 63614 77 64435036
Therapy change 15.62 15.05 25 63594 6409 64428704
Type 2 diabetes mellitus 15.59 15.05 7 63612 34013 64401100
Skin ulcer 15.58 15.05 85 63534 43889 64391224
Sleep apnoea syndrome 15.57 15.05 5 63614 29827 64405286
Gingival recession 15.54 15.05 11 63608 1092 64434021
Anal ulcer 15.49 15.05 11 63608 1098 64434015
Bradycardia 15.47 15.05 62 63557 118157 64316956
Myoclonus 15.45 15.05 3 63616 25115 64409998
Seizure 15.31 15.05 99 63520 166793 64268320
Haemorrhage 15.28 15.05 132 63487 79219 64355894
Scrotal ulcer 15.24 15.05 7 63612 302 64434811
Proctalgia 15.20 15.05 27 63592 7532 64427581
Headache 15.16 15.05 402 63217 529065 63906048
Nasal discomfort 15.16 15.05 20 63599 4308 64430805

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50846 Immunologic factor
CHEBI has role CHEBI:62434 ALK inhibitor
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Renal cell carcinoma indication 702391001 DOID:4450
Pancreatic Neuroendocrine Tumor indication 717919005
Acute hemorrhage contraindication 8573003
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Hemoptysis contraindication 66857006
Hypermagnesemia contraindication 66978005
Pancreatitis contraindication 75694006 DOID:4989
Heart failure contraindication 84114007 DOID:6000
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Posterior reversible encephalopathy syndrome contraindication 450886002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.52 acidic
pKa2 11.68 acidic
pKa3 12.32 acidic
pKa4 9.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 10.12 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 9.66 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Ki 7.77 CHEMBL CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase INHIBITOR Kd 8.70 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR IC50 8.80 IUPHAR DRUG LABEL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.23 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 6.96 SCIENTIFIC LITERATURE DRUG LABEL
Epidermal growth factor receptor Kinase Kd 6.07 CHEMBL
Pyridoxal kinase Kinase Kd 5.22 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.68 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.64 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.92 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.28 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.26 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 8.23 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 5.59 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Insulin receptor Kinase AGONIST Kd 6.74 CHEMBL
Death-associated protein kinase 3 Kinase Kd 7.66 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 6.01 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 6.54 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.34 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.36 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.06 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.05 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.92 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 7 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6.39 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.85 CHEMBL
Protein kinase C alpha type Kinase Kd 5.22 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 6.38 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 7.31 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 6.36 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.96 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 6.51 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.30 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.77 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.72 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase Kd 5.85 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 6.28 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 8.26 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.16 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.72 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.72 CHEMBL
Aurora kinase C Kinase Kd 6.66 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.60 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.20 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.92 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.28 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.15 CHEMBL
Protein kinase C theta type Kinase Kd 5.37 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 9 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.02 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.60 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 7.89 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.57 CHEMBL
Aurora kinase A Kinase Kd 5.77 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 6.77 CHEMBL
Serine/threonine-protein kinase pim-2 Kinase Kd 5.30 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.28 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 7.66 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 7.70 CHEMBL
Serine/threonine-protein kinase 38-like Kinase Kd 6.01 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.39 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 5.48 CHEMBL
Cyclin-G-associated kinase Kinase Kd 7.70 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.32 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.29 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 6.89 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 7.72 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.66 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 7.77 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.25 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.54 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 5.24 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.62 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.39 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.38 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.36 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 5.70 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.21 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.20 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.46 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6.89 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 6.96 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 7.89 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 5.34 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 5.68 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 8.05 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.23 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 7.31 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.48 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6.51 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.89 CHEMBL
RAC-beta serine/threonine-protein kinase Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.25 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.62 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.82 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.52 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.96 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 7.80 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.92 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 5.77 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.57 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.27 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.41 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 7.82 CHEMBL
Wee1-like protein kinase Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 6.54 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.46 CHEMBL
Casein kinase I isoform alpha-like Kinase Kd 6.26 CHEMBL
Casein kinase I isoform delta Kinase Kd 7.82 CHEMBL
Casein kinase I isoform gamma-2 Kinase Kd 6.96 CHEMBL
Casein kinase I isoform gamma-3 Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase tousled-like 1 Kinase Kd 6.13 CHEMBL
Serine/threonine-protein kinase tousled-like 2 Kinase Kd 6.48 CHEMBL
NT-3 growth factor receptor Kinase Kd 5.29 CHEMBL
Casein kinase II subunit alpha Kinase Kd 7.09 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.80 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.64 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.42 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.77 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 6.46 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.39 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 6.74 CHEMBL
Insulin receptor-related protein Kinase Kd 6.37 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 6.03 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.42 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.24 CHEMBL
SRSF protein kinase 1 Kinase Kd 6.60 CHEMBL
SRSF protein kinase 2 Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 7.77 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.05 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.51 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 5.54 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.20 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.34 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.74 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.80 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 6.19 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase pim-3 Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.74 CHEMBL
Aurora kinase B Kinase Kd 6.42 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 7.19 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase BRSK1 Kinase Kd 5.46 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.92 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.44 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 6.15 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.28 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 7.59 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 6.05 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.47 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 7.20 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.31 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.41 CHEMBL
Casein kinase I isoform gamma-1 Kinase Kd 6.03 CHEMBL
Death-associated protein kinase 1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.43 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 5.57 CHEMBL
Myosin-IIIa Kinase Kd 5.51 CHEMBL
Myosin-IIIb Kinase Kd 5.35 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase BRSK2 Kinase Kd 5.96 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 5.99 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.49 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.55 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 6.17 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.43 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.02 CHEMBL
Fibroblast growth factor receptor 4 Kinase Kd 5.68 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 7.02 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 7.02 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Kinase IC50 4.89 CHEMBL
Casein kinase I isoform alpha Kinase Kd 7 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 7.48 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.54 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.92 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 7.18 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 5.70 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 8.15 CHEMBL
Protein delta homolog 1 Unclassified Kd 7 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase Kd 6.70 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 6.17 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.07 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 6.22 CHEMBL
Rhodopsin kinase Kinase Kd 6.54 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 6.85 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 6.74 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 7.51 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 7.39 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.80 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 6.30 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 6.33 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 6.28 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 7.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 7.02 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.24 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.66 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.70 CHEMBL
Serine/threonine-protein kinase 38 Kinase Kd 6.39 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 6.07 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 6.28 CHEMBL
U4/U6 small nuclear ribonucleoprotein Prp4 Nuclear other Kd 6.41 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 7.31 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.23 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 7.03 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.05 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.68 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 7.64 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.37 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.38 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.77 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 7.26 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 5.33 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 5.89 CHEMBL
Tankyrase-2 Enzyme Kd 5.05 CHEMBL
Megakaryocyte-associated tyrosine-protein kinase Kinase Kd 5.11 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.70 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 6.41 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 7 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6.66 CHEMBL
SNF-related serine/threonine-protein kinase Kinase Kd 6.19 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 7.34 CHEMBL
Myosin light chain kinase 3 Kinase Kd 7.64 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.12 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 5.89 CHEMBL
Bromodomain-containing protein 9 Unclassified Kd 4.77 CHEMBL
Mitotic checkpoint serine/threonine-protein kinase BUB1 Kinase Kd 5.46 CHEMBL
TFIIH basal transcription factor complex helicase XPD subunit Enzyme Kd 5.91 CHEMBL
G protein-coupled receptor kinase 6 Kinase Kd 5.79 CHEMBL
5'-AMP-activated protein kinase subunit gamma-1 Kinase Kd 5.94 CHEMBL
Uncharacterized protein FLJ45252 Unclassified Kd 6.37 CHEMBL
5'-AMP-activated protein kinase subunit gamma-2 Kinase Kd 5.76 CHEMBL
G protein-coupled receptor kinase 5 Kinase IC50 6.08 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 5.62 SCIENTIFIC LITERATURE
Ephrin type-B receptor 4 Kinase Kd 5.51 SCIENTIFIC LITERATURE
Serine/threonine-protein kinase ULK2 Kinase Kd 7.89 CHEMBL
Death-associated protein kinase 2 Kinase Kd 6.82 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.68 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.26 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.92 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.30 CHEMBL
Acetylcholinesterase Enzyme IC50 5.23 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme Kd 5.40 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 7.26 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6.80 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.96 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.26 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 7.06 CHEMBL

External reference:

IDSource
4025079 VUID
N0000175350 NUI
D06402 KEGG_DRUG
341031-54-7 SECONDARY_CAS_RN
4025079 VANDF
4025080 VANDF
C1176020 UMLSCUI
CHEBI:38940 CHEBI
B49 PDB_CHEM_ID
CHEMBL535 ChEMBL_ID
CHEMBL1567 ChEMBL_ID
D000077210 MESH_DESCRIPTOR_UI
DB01268 DRUGBANK_ID
5329102 PUBCHEM_CID
5713 IUPHAR_LIGAND_ID
8646 INN_ID
V99T50803M UNII
357977 RXNORM
20930 MMSL
21012 MMSL
349534 MMSL
75586 MMSL
d05717 MMSL
011192 NDDF
011193 NDDF
421192001 SNOMEDCT_US
421448007 SNOMEDCT_US
426455008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0550 CAPSULE 12.50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0770 CAPSULE 25 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0830 CAPSULE 37.50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0980 CAPSULE 50 mg ORAL NDA 34 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0093-8199 CAPSULE 12.50 mg ORAL ANDA 31 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0093-8224 CAPSULE 25 mg ORAL ANDA 31 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0093-8229 CAPSULE 37.50 mg ORAL ANDA 31 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0093-8231 CAPSULE 50 mg ORAL ANDA 31 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6678 CAPSULE 12.50 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6678 CAPSULE 12.50 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6679 CAPSULE 25 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6679 CAPSULE 25 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6680 CAPSULE 50 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6680 CAPSULE 50 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6681 CAPSULE 37.50 mg ORAL ANDA 30 sections
Sunitinib Malate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6681 CAPSULE 37.50 mg ORAL ANDA 30 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 16714-676 CAPSULE 12.50 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 16714-677 CAPSULE 25 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 16714-678 CAPSULE 37.50 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 16714-679 CAPSULE 50 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 63304-091 CAPSULE 12.50 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 63304-092 CAPSULE 25 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 63304-093 CAPSULE 37.50 mg ORAL ANDA 29 sections
Sunitinib malate HUMAN PRESCRIPTION DRUG LABEL 1 63304-094 CAPSULE 50 mg ORAL ANDA 29 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 63539-017 CAPSULE 12.50 mg ORAL NDA 34 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 63539-019 CAPSULE 50 mg ORAL NDA 34 sections